Absorption of different curcumin formulations

Comparative absorption of different curcumin formulations

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN28011391

Enrollment

Registered

2013-09-13

Start date

2013-05-02

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A Not Applicable

Interventions

Frequency: Single dose, randomized, double blinded, cross-over study design

Dose: 376 mg for (BCM-95® [Dolcas], Meriva® [Indena], and Curcumax UltraSol Dry Nutrient System™ [DNS] [OmniActive]), and 1800 mg for C3 Complextrade mark, (Sabinsa Corporation). Intervention: Subject

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Normal Healthy Individuals 2. Age: 18-55 y 3. Males and females 4. Must be able to perform required testing 5. Participants agreed to sign an informed consent form

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Use of prescription medications 3. Gastrointestinal conditions 4. Diabetics 5. Alcohol and/or substance abuse history, and/or allergies to turmeric or curcumin 6. Subjects consuming any foods or supplements containing curcumin

Design outcomes

Primary

Measure	Time frame
1. Peak plasma concentrations (TMax), 2. Areas under the plasma concentration-time curves (AUC0-6h, AUC0-12h and AUC0-a), CMax and t1/2 Plasma levels of major curcuminoids [curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin] will be evaluated at 0, 1, 2, 3, 4, 5, 6, 8 and 12 hours. Peak plasma concentrations (TMax), areas under the plasma concentration-time curves (AUC0-6h, AUC0-12h and AUC0-a), CMax and t1/2 will be calculated.	—

Measure

Time frame

1. Peak plasma concentrations (TMax), 2. Areas under the plasma concentration-time curves (AUC0-6h, AUC0-12h and AUC0-a), CMax and t1/2 Plasma levels of major curcuminoids [curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin] will be evaluated at 0, 1, 2, 3, 4, 5, 6, 8 and 12 hours. Peak plasma concentrations (TMax), areas under the plasma concentration-time curves (AUC0-6h, AUC0-12h and AUC0-a), CMax and t1/2 will be calculated.

—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026